Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
60% of hypopharyngeal cancers were locally advanced at the time of diagnosis. The standard
treatment was surgery and postoperative radiotherapy. Compared with traditional surgery and
postoperative radiotherapy, induction chemotherapy combined with radiotherapy has a better
laryngeal retention rate without reducing the curative effect, and established an organ
function preservation treatment strategy. Induction chemotherapy can reduce tumor burden and
reduce distant metastases. At present, induction chemotherapy followed by concurrent
chemoradiotherapy has become the standard treatment for the laryngeal preservation in locally
advanced hypopharyngeal and laryngeal cancer. This study aimed to investigate the efficacy
and safety of a PD-1 inhibitor toripalimab combined with chemotherapy as induction therapy in
hypopharyngeal cancer.